We found two SNPs rs4645948 (C>T) and rs2071346 (G>T) were significantly associated with increased risk of developing NPC (TT+CT <i>vs</i> CC, OR=1.557, P=3.34×10<sup>-4</sup>; TT+GT <i>vs</i> GG, OR=1.361, P=0.007, respectively).
We also found rs2071346 (G>T) variant genotype carriers were subjected to higher risk of anemia (GT <i>vs</i> GG, OR=1.665, P=0.022) and thrombocytopenia (GT <i>vs</i> GG, OR=1.685, P=0.035).
In addition, rs4645948 (C>T) was conferred with increased risk of anemia (CT <i>vs</i> CC, OR=2.152, P=0.001) and severe leukopenia (CT <i>vs</i> CC, OR=1.893, P=0.034) for NPC patients receiving chemoradiotherapy.
These findings suggested that individual carrying the rs4645948 T allele may be at greater risk for NPC due to an increase of MYC transcriptional activity and an augment of MYC expression.
In addition, rs4645948 (C>T) was conferred with increased risk of anemia (CT <i>vs</i> CC, OR=2.152, P=0.001) and severe leukopenia (CT <i>vs</i> CC, OR=1.893, P=0.034) for NPC patients receiving chemoradiotherapy.
We determined that one SNP allele (rs3824120) in a CpG island associated with MYC which eliminated a CpG was more common in the cancer datasets than in the 100Genomes databases (p < 0.01).
We determined that one SNP allele (rs3824120) in a CpG island associated with MYC which eliminated a CpG was more common in the cancer datasets than in the 100Genomes databases (p < 0.01).
We also identified a SNP achieving array wide significance (MYC: rs2070583, allele frequency 0.02, P = 8.1 × 10(-8)), but the association did not replicate in an additional 8,059 African Americans (577 events) from the WHI, HealthABC and GeneSTAR studies, and in a meta-analysis of 5 cohort studies of European ancestry (24,024 individuals including 1,570 cases of MI and 2,406 cases of CHD) from the CHARGE Consortium.
Among the 78 BLs in this series, an additional five had RHOA mutations resulting in a total incidence of 7/82 (8.5%) with c.14G>A (p.R5Q) being present in three cases.
Among the 78 BLs in this series, an additional five had RHOA mutations resulting in a total incidence of 7/82 (8.5%) with c.14G>A (p.R5Q) being present in three cases.
Among the 78 BLs in this series, an additional five had RHOA mutations resulting in a total incidence of 7/82 (8.5%) with c.14G>A (p.R5Q) being present in three cases.
A joint analysis of the Polish and the German study population revealed a 54% increased risk for breast cancer associated with the heterozygous Asn11Ser variant (OR = 1.54, 95% CI 1.05-2.26, p = 0.028).
Here, we analysed the influence of the rare c-MYC Asn11Ser polymorphism on familial breast cancer risk by performing a case-control study with a Polish (cases n = 349; controls n = 441) and a German (cases n = 356; controls n = 655) study population.
A joint analysis of the Polish and the German study population revealed a 54% increased risk for breast cancer associated with the heterozygous Asn11Ser variant (OR = 1.54, 95% CI 1.05-2.26, p = 0.028).